Sanara MedTech appoints Zachary B. Fleming as CEO

Sanara MedTech appoints Zachary B. Fleming as CEO

Sanara MedTech Inc., a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, appointed Zachary (“Zach”) B. Fleming as CEO effective January 1, 2022.

Fleming joined Sanara as VP of sales during November 2017. He was promoted to president of the Surgical Division in May 2019 and as co-chief operating officer during January 2020. Before Sanara, Fleming held several sales and management roles at Healthpoint Biotherapeutics and Smith & Nephew plc.

Sanara’s Executive Chairman Ron Nixon said, “Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy. During his time as president of the Surgical Division, he has overseen double-digit year-over-year revenue growth of our business and steered the division through the challenges associated with the COVID-19 pandemic. The board of directors and I are confident that he will bring the same leadership skills, strategic vision, and industry expertise to his new role as CEO. I look forward to continuing to work closely with him as we execute our comprehensive wound and skin care strategy.”

Fleming stated, “I am proud of what our team has accomplished to date for all of our stakeholders, including the patients, doctors, and clinicians who use our products. I am looking forward to the opportunity to lead the Sanara MedTech team, and to continue to work with Ron and the entire Sanara MedTech Board to execute our strategy. Together, we will work to expand our surgical product offering, implement Sanara’s comprehensive wound and skin strategy, and fulfill our mission of providing products and technologies that offer a value-based solution while improving outcomes for wound patients.”